NASDAQ:GOSS Gossamer Bio Q3 2026 Earnings Results & Report $11.28 +0.63 (+5.92%) Closing price 04:00 PM EasternExtended Trading$10.30 -0.98 (-8.67%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Gossamer Bio missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$7.36 versus the -$3.79 consensus estimate, while revenue of $38.43 million topped the $12.16 million estimate by $26.27 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Gossamer Bio EPS ResultsActual EPS-$7.36Consensus EPS -$3.79Beat/MissMissed by -$3.57One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersGossamer Bio Revenue ResultsActual Revenue$38.43 millionExpected Revenue$12.16 millionBeat/MissBeat by +$26.27 millionYoY Revenue GrowthN/AUpcoming EarningsGossamer Bio's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gossamer Bio Q3 2026 Earnings FAQ Did Gossamer Bio beat earnings estimates for Q3 2026? Gossamer Bio (NASDAQ:GOSS) reported earnings of -$7.36 per share for Q3 2026, missing the consensus estimate of -$3.79. The report was announced on Tuesday, November 10, 2026. What was Gossamer Bio's revenue for Q3 2026? Gossamer Bio reported revenue of $38.43 million for Q3 2026, against a consensus estimate of $12.16 million. When is Gossamer Bio's next earnings date? Gossamer Bio's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Gossamer Bio on the company's earnings history page. Gossamer Bio Earnings HeadlinesGossamer Bio (GOSS) Set to Announce Quarterly Earnings on WednesdayNovember 2, 2026 | americanbankingnews.comGossamer Bio stockholders approve share issuance proposal under securities purchase agreement dated August 20, 2026October 28, 2026 | msn.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 10 at 1:00 AM | Behind the Markets (Ad)Gossamer Bio (GOSS) Stock Sees Fair Value Lift As Analysts Weigh Seralutinib RisksOctober 17, 2026 | finance.yahoo.comChardan Initiates Gossamer Bio at Buy With $160 Price TargetOctober 13, 2026 | marketscreener.comMGossamer Bio average analyst price target decreased by 40.76% to $80.05October 2, 2026 | msn.comSee More Gossamer Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email. Email Address About Gossamer BioGossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company has also pursued additional investigational programs in immunology and inflammatory diseases. Gossamer Bio was founded in 2015 and is headquartered in San Diego, California. Its programs are advanced through clinical development and collaborations intended to support development and potential commercialization in the United States and international markets. The company’s leadership includes Chief Executive Officer Faheem Guirgis.View Gossamer Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
